148 related articles for article (PubMed ID: 36812231)
1. Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data.
Liu N; Liang BL; Lu L; Zhang BQ; Sun JJ; Yang JT; Xu J; Song ZB; Shi L
Neoplasma; 2023 Apr; 70(2):300-310. PubMed ID: 36812231
[TBL] [Abstract][Full Text] [Related]
2. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
[TBL] [Abstract][Full Text] [Related]
5. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
6. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
9. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
10. Application of 18 F-fluorodeoxyglucose PET/CT radiomic features and machine learning to predict early recurrence of non-small cell lung cancer after curative-intent therapy.
Park SB; Kim KU; Park YW; Hwang JH; Lim CH
Nucl Med Commun; 2023 Feb; 44(2):161-168. PubMed ID: 36458424
[TBL] [Abstract][Full Text] [Related]
11. Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Acta Radiol; 2023 Mar; 64(3):1194-1204. PubMed ID: 35971221
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
14. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
17. Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.
Kim KH; Kim J; Park H; Kim H; Lee SH; Sohn I; Lee HY; Park WY
Thorac Cancer; 2020 Sep; 11(9):2542-2551. PubMed ID: 32700470
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment
Ahn HK; Lee H; Kim SG; Hyun SH
Clin Radiol; 2019 Jun; 74(6):467-473. PubMed ID: 30898382
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features.
Bashir U; Kawa B; Siddique M; Mak SM; Nair A; Mclean E; Bille A; Goh V; Cook G
Br J Radiol; 2019 Jul; 92(1099):20190159. PubMed ID: 31166787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
